Oxypurinol alkali and alkalane earth salts in amorphous or crystalline form as agents for treating hyperuricaemia and gout
US5430037A · kind A · utility
2Cited by
0References
3Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jan 19, 1993 |
| Grant date | Jul 4, 1995 |
| Priority date | — |
| Expiry date | Jan 19, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/519
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Treatment of hyperuricaemia and gout is possible by agents, among usual carriers and adjuvants containing pharmakologically active doses of oxypurinol alkali and/or alkaline earth salts in amorphous or crystalline form.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.